Patent Extensions Get Bureaucratic Tune-Up Over FDA Delays
Published Date: 11/19/2025
Notice
Summary
The USPTO is asking for public feedback on updating the paperwork for extending patent protection when FDA or USDA delays slow down approval of drugs, medical devices, or food additives. This update affects companies holding these patents and aims to keep the process smooth and fair. Comments are open until January 20, 2026, so don’t miss your chance to weigh in!
Analyzed Economic Effects
4 provisions identified: 1 benefits, 2 costs, 1 mixed.
Estimated time and dollar burden to respond
The USPTO estimates 903 annual respondents and 903 annual responses, totaling 6,807 burden hours and an estimated $3,042,729 in hourly cost burden; responses are expected to take about 1 to 25 hours each. The agency estimates total annual non-hour costs (filing fees and postage) of $489,431.
Filing fees for extension-related filings
The notice lists specific filing fees for extension-related items: Application to extend a patent under 35 U.S.C. 156 is $2,500 (estimated 134 responses); initial interim extension under 35 U.S.C. 156(d)(5) is $1,320 (4 responses); subsequent interim extension is $680 (3 responses); petition for reconsideration of patent term adjustment is $226 (622 responses); supplemental redetermination fee is $1,440 (4 responses); petition for reinstatement fee is $452 (1 response); petition to accord a filing date is $226 (1 response).
Patent-term extensions for regulated products
If you hold a patent for a drug, medical device, food additive, or color additive, you can apply to the USPTO to extend the patent term to compensate for FDA or USDA regulatory review delays. The application must identify the approved product, the patent and claims covering the product or its manufacture/use, and a brief description with dates of activities during the regulatory review period; a patent may be extended up to 5 years under 35 U.S.C. 156.
Right to petition reinstatement of reduced adjustment
If the USPTO reduces a granted patent term adjustment because an applicant failed to reasonably respond within three months to a USPTO communication, the applicant may petition for reinstatement of the reduced adjustment by showing that, despite all due care, they were unable to respond within the three-month period.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16744, Request for Comments on Community Outreach Office Locations in the Southwest States
The USPTO wants your ideas on where to open new community outreach offices in the Southwest states like Arizona and Texas. These offices will help inventors, small businesses, and students get better support with patents. Share your thoughts by September 16, 2026, so the USPTO can pick the best spots and keep innovation booming without extra costs to you!
2026-16315, Administrative Updates to the General Requirements Bulletin for Admission to the Examination for Registration To Practice in Patent Cases Before the United States Patent and Trademark Office
Starting August 11, 2026, the USPTO is upgrading Biomedical Science degrees from Category B to Category A for patent bar eligibility. This means more people with this degree can now take the patent exam and become patent practitioners. No extra fees or delays—just a smoother path for those with the right science background to join the patent world!
2026-14941, Grant of Interim Extension of the Term of U.S. Patent No. 8,461,196; Centanafadine Hydrochloride
Otsuka America Pharmaceutical got a one-year extra patent life for their drug centanafadine hydrochloride because the FDA review is still going on. This means they keep exclusive rights to the drug until July 25, 2027, giving them more time to sell it without competition. This extension helps the company protect their investment while the drug gets final approval.
2026-14939, Grant of Interim Extension of the Term of U.S. Patent No. 8,877,798; Centanafadine Hydrochloride
Otsuka America Pharmaceutical got a one-year extra patent life for their drug centanafadine hydrochloride because the FDA review is still going on. This means their patent, which was set to expire on July 25, 2026, now lasts until July 25, 2027. This extension helps Otsuka keep exclusive rights to their drug a bit longer while waiting for final FDA approval.
2026-14793, Requirement To Identify All Real Parties in Interest to a Third Party Request for an Ex Parte Reexamination
The USPTO wants anyone asking for a third-party ex parte reexamination to clearly say who’s really behind the request. This helps stop sneaky tricks and keeps the process honest. If you’re involved, get ready to share this info confidentially by August 21, 2026, or risk delays or issues.
2026-14388, Agency Information Collection Activities; Submission to the Office of Management and Budget for Review and Approval; Comment Request; Admission to Practice and Roster of Registered Patent Attorneys and Agents Admitted to Practice Before the United States Patent and Trademark Office
The USPTO is asking for public feedback on its paperwork rules for patent attorneys and agents who want to practice before the office. This helps keep the process smooth and fair without making people fill out too many forms. If you have thoughts, send them in by August 17, 2026—no fees or big changes are happening right now, just a review.
Previous / Next Documents
Previous: 2025-20242, Notice of Guidance: Transporting Hazardous Materials by Unmanned Aircraft Systems (UAS)
Starting November 19, 2025, the FAA and PHMSA teamed up to share new guidance for safely flying drones that carry hazardous materials. This affects companies using drones for deliveries, setting clear rules based on what’s being carried and how much. If you’re in the drone delivery game, check out the rules and send your feedback by December 19, 2025—this could shape future drone flights and safety standards!
Next: 2025-20244, Agency Information Collection Activities; Submission to the Office of Management and Budget for Review and Approval; Comment Request; Deposit of Biological Materials
The USPTO is asking for public feedback on updating the rules for depositing biological materials when applying for patents. This affects inventors and institutions handling these materials, with a comment deadline of January 20, 2026. No new fees are mentioned, but the update helps keep the process clear and smooth for everyone involved.